Will patient prevalence play a larger role in TLV’s assessments?
That’s a possible conclusion to draw from Sweden’s HTA body The Dental and Pharmaceutical Benefits Agency, TLV‘s report published this week, on the topic of improving access to drugs for rare diseases.https://www.linkedin.com/company/tlv-the-dental-and-pharmaceutical-benefits-agency/
The pharmaceutical market has shifted in […]